Ocular Therapeutix Set to Unveil Phase 3 Wet AMD Trial Results
Event summary
- Ocular Therapeutix will announce topline data from the SOL-1 Phase 3 superiority trial for AXPAXLI (OTX-TKI) in wet AMD on February 17, 2026.
- Detailed results will be presented at the 49th Macula Society Annual Meeting (February 25–28, 2026).
- AXPAXLI is an axitinib intravitreal hydrogel based on Ocular’s ELUTYX proprietary bioresorbable hydrogel technology.
- The company also has OTX-TIC in its pipeline, a travoprost intracameral hydrogel for open-angle glaucoma, currently evaluating next steps.
The big picture
Ocular Therapeutix’s upcoming Phase 3 trial results for AXPAXLI in wet AMD could reshape the retinal disease treatment landscape. The trial’s success or failure will influence the company’s valuation and strategic positioning in the competitive ophthalmology market. The broader biotech sector will be watching closely, as the outcome may set a precedent for hydrogel-based therapies in retinal conditions.
What we're watching
- Clinical Efficacy
- Whether AXPAXLI demonstrates superiority over existing wet AMD treatments in the Phase 3 trial results.
- Regulatory Pathway
- The timeline for potential regulatory submissions based on the trial outcomes.
- Pipeline Strategy
- How Ocular Therapeutix will advance its other programs, particularly OTX-TIC, following the AXPAXLI data.
Related topics